STK25 and hepatocellular carcinoma: We next compared the cell-autonomous mode of action of STK25 antagonism to that of 2 anti-HCC drugs approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA): small molecule multi-kinase inhibitors sorafenib (the first-line standard of care for advanced HCC [stage C]) and regorafenib (the second-line therapy for sorafenib-resistant HCC).2